RxDoctor Payments DataLook up a doctor →

Nayan Desai, MD

Interventional Cardiology · Bismarck, NDNPI 1316368236

Payments from drug & device makers

$414,710in general payments, 2019–2025

Across 720 payments — averaging $575.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$88K
  • Actelion Pharmaceuticals US, Inc.$81K
  • Alnylam Pharmaceuticals Inc.$43K
  • Edwards Lifesciences$42K
  • Johnson & Johnson$40K
  • Boehringer Ingelheim$29K
  • plus $91K from 31 others

What the payments were for

  • Consulting fees$73,13018%
  • Speaking & faculty fees$248,81360%
  • Grants$50,00012%
  • Travel & lodging$28,3987%
  • Food & beverage$11,9913%
  • Education$3790%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few interventional cardiology providers in North Dakotato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$505,256
Medicare patients
2,444
Services billed
6,613

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis23$846,265
OpsumitMacitentan43$630,394
EliquisApixaban462$399,601
Orenitram ErTreprostinil Diolamine12$308,977
JardianceEmpagliflozin168$153,243
XareltoRivaroxaban162$147,481
MounjaroTirzepatide97$103,627
EntrestoSacubitril/Valsartan83$88,738
FarxigaDapagliflozin Propanediol96$54,701
Repatha SureclickEvolocumab65$40,060
Praluent PenAlirocumab36$21,032
BrilintaTicagrelor42$16,770
Metoprolol Succinate808$14,875
Synjardy XrEmpagliflozin/Metformin Hcl12$14,813
Repatha SyringeEvolocumab19$13,491

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Eliquis$88,200$1,245,866485 claims
Actelion Pharmaceuticals US, Inc.Opsumit$80,971$630,39443 claims
Boehringer IngelheimJardiance, Synjardy Xr$29,328$168,057180 claims
Johnson & JohnsonXarelto$39,601$147,481162 claims
Lilly USA, LLCMounjaro$20,642$103,62797 claims
NovartisEntresto$104$88,73883 claims
AstraZenecaFarxiga, Brilinta$15,585$71,471138 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few interventional cardiology providers in North Dakotaon file to place this against a meaningful peer group, so we don't.

Other interventional cardiology in Bismarck

See the full list for North Dakota

Where these figures come from

Is this you, or does something look wrong? →